A Phase 1 interventional study of PRT064445 and Placebo in Healthy, sponsored by Portola Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-04.
Sponsored by Portola Pharmaceuticals (part of AstraZeneca) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a single center, double-blind, randomized, placebo-controlled, ascending, single dose study of PRT064445 or its matching placebo, in healthy subjects.
Portola Pharmaceuticals is the lead sponsor of 23 studies on the registry; none are open to participants now.
First submitted before Portola Pharmaceuticals became part of AstraZeneca.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dose 1 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 2 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 3 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 4 versus Placebo
Biological: PRT064445 · Drug: Placebo
Dose 5 versus Placebo
Biological: PRT064445 · Drug: Placebo
Intravenous
Intravenous to mimic PRT064445
Also known as: Placebo (for PRT064445)
Pharmacodynamics assessments
Time frame: Up to 28 days
Pharmacokinetics: Plasma levels of PRT064445
Time frame: Up to 7 days
The record gives a start of Jun 2012, a primary completion of Sep 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PRT064445